Adcetris Maker Launches Trials for New Agent Against ALL and B-Cell NHL

Seattle Genetics, maker of the antibody drug conjugate Adcetris, has announced the initiation of a pair of Phase I clinical trials testing the company's latest oncology candidate, SGN-CD19A.

Each trial will serve to assess the safety and anti-tumor response of SGN-CD19A against both CD19-positive acute lymphoblastic leukemia (ALL) as well as B-cell non-Hodgkin's lymphoma (HL).

Primary endpoints of the trials include determining the maximum tolerated dose as well as investigating the safety of SGN-CD19A. Secondary endpoints will include antitumor activity, pharmacokinetics, progression-free survival (PFS) and overall survival (OS).

Adcetris, the company's only approved drug, generated more than $100 million during the first nine months of 2012 and is now approved under Health Canada's Notice of Compliance with conditions (NOC/c) for the treatment of relapsed or refractory Hodgkin's as well as systemic anaplastic large cell lymphoma (sALCL) - conditions for which it is approved by the U.S. FDA as well.

Most recently, a global phase III study known as ECHELON-2 was launched, investigating Adcetris plus chemotherapy as a potential first-line therapy against CD30-positive mature T-cell lymphoma (MTCL).

ECHELON-2 was initiated in January. 

Source: Leukemia & Lymphoma Society

More Articles

More Articles

According to a study by Japanese researchers, the SMILE combination chemotherapy protocol is effective against extranodal natural killer/T-cell...

Patients treated with maintenance rituximab had three times longer progression-free survival. This is a summary of an article published in the...

When you consider that the adult human body has anywhere from 300 to 700 lymph nodes, the better question might not be where ARE they located, but...

This entry looks at a non-Hodgkin's lymphoma called true histiocytic lymphoma (THL), also referred to as diffuse histiocytic lymphoma, and...

Lymphomatous meningitis [LM], also known as leukemic meningitis, is an extremely serious peripheral cancer that attacks the tissue that covers the...

Hodgkin's Disease—also referred to as Hodgkin's Lymphoma, these are the exact same diseases, just...

Intravascular lymphoma is a subtype of 'Lymphoma', an umbrella term that loosely refers to several dozen...

While the average lifespan for hamsters is only about 2.5 years, and they are therefore less prone to long-term illnesses, it is possible for a...

Burkitt's lymphoma is an aggressive B-cell lymphoma that is common in children...

Lymphoma is a cancer of the lymphatic system, causing B-cell or...

The term NK T cell lymphoma refers to one of two subtypes of lymphoma that affect the NK (Natural Killer)...

Lymphoma is a life-threatening disease, but is very treatable in most cases. The 5-year survival for patients diagnosed with non-Hodgkin's...

T cell lymphoma treatment options for these cancers are not especially effective and there is no absolute consensus about optimal treatments for...

Marginal zone lymphomas (MZL) are indolent lymphomas that affect the B-cells. The...

Lymphomas can arise from most any lymphatic tissue (lymph nodes, spleen, thymus, mucosa associated lymphoid...